RecruitingPhase 1NCT04903223

Liver Adiposity Effects on Pediatric Statin

Effects of Pediatric Liver Adiposity on Statin Disposition and Response

Sponsor

Children's Mercy Hospital Kansas City

Enrollment

50 participants

Start Date

Apr 1, 2021

Study Type

INTERVENTIONAL

Conditions

Cholesterol; Lipidosis

Summary

Single center, open-label, prospective investigation to quantify the effects hepatocellular fat has on hepatic statin transport and response in children and adolescents in obese and non-obese children and adolescents 8-21 years of age with normal, wild-type SLCO1B1 c.521TT genotype that are dosed rosuvastatin

Eligibility

Min Age: 8 YearsMax Age: 21 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Rosuvastatin 10mg for people with cholesterol; lipidosis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 8 Years to 21 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRosuvastatin 10mg

Rosuvastatin will be administered to all participants on Study Day #2

Locations(1)

Children's Mercy Hospital

Kansas City, Missouri, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04903223